ODYSSEY OUTCOMES: Evaluating the clinical impact of PCSK9 inhibitor therapy over time

ODYSSEY OUTCOMES demonstrated that attainment of very low LDL cholesterol levels in acute coronary syndrome (ACS) patients reduces first cardiovascular events. But, given that ACS patients are at high risk of recurrent events, what is the impact of this treatment on the longer-term total cardiovascular burden?

In a new analysis of this trial, alirocumab treatment avoided twice as many nonfatal cardiovascular events or deaths compared with first events. These findings have important implications when weighing the societal costs of add-on PCSK9 inhibition in very high-risk patients.

PCSK9 Forum Editor Professor John Chapman (INSERM and University of Pierre and Marie Curie-Sorbonne, Paris, France) discusses implications of this analysis Read the report here »

Dr Michael Szarek (SUNY Downstate School of Public Health, New York, USA, and a member of the Executive Steering Committee of the ODYSSEY Outcomes Trial) discusses this analysis.
	Rationale, methods and key results		Take home messages for clinicians